Prosetta Biosciences, Inc. is a 12-year old biotechnology company focused on developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS).
Our CFPSS drug discovery platform allows for identification of small molecule drugs which may be missed with traditional pharma screening methods.
Prosetta has successfully produced highly potent compounds which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids and display activity against multiple strains of many viral families.
Our CFPSS drug discovery platform allows for identification of small molecule drugs which may be missed with traditional pharma screening methods.
Prosetta has successfully produced highly potent compounds which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids and display activity against multiple strains of many viral families.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $38M
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.12.2015 | Series D | $31M | - |
| 26.11.2008 | - | $5M | - |
| 18.05.2007 | - | $2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.12.2015 | Prosetta Biosciences Raises $31M in Series D | SAN FRANCISCO, CA, Prosetta Biosciences has raised approximately $31 million in a Series D private placement. >> Click here for more funding data on Prosetta Biosciences >> To export Prosetta Biosciences funding data to PDF ... |
| 04.12.2015 | Daily funding roundup - December 4, 2015 | iPinYou bagged $78M; Prosetta raised $31M; ZeroFox secured an additional $27M funding Desino, a Cologne, Germany-based wheelchair manufacturer, completed a €500,000 (approximately $546,000) Series A funding round. Backers included Prof. Mic... |
| 04.12.2015 | Prosetta Biosciences Raises $31M in Series D Funding | Prosetta Biosciences, Inc., a San Francisco, CA-based biotechnology company focused on human and animal treatments and therapeutics, raised approximately $31m in Series D funding. Backers included Alger Management and Takeda Pharmaceutical ... |
| 04.12.2015 | Takeda backs antiviral maker Prosetta Biosciences in $31M round | The company says it’s produced a series of compounds that alter the assembly of the protein shell, or capsid, that encircles the DNA or RNA genome of a virus. It’s screened tens of thousands of small molecules over the past decade, seeking ... |
| 26.11.2008 | Prosetta takes $5M from angels for anti-viral drugs | San Francisco drug developer Prosetta announced that it brought in $5 million in second-round funding to begin clinical trials on its lead compounds. All of the contributors were individuals, reports VentureWire. So far, the company has res... |
| 07.08.2007 | Pelosi’s biotech defense pork | House Speaker Nancy Pelosi apparently has a warm spot in her heart for two San Francisco life-science companies. Thanks to Rep. Pelosi., biotech companies Prosetta, which is focused on new antiviral drugs, and Bioquiddity (no link; it is ke... |
| 07.08.2007 | Nancy Pelosi’s biotech earmarks | (UPDATED: See below.) House Speaker Nancy Pelosi apparently has a warm place in her heart for two San Francisco life-science companies. Buried inside a story on how the Democrat-led Congress seems almost as enthusiastic as its scandal-ridde... |
| 21.05.2007 | Prosetta, antiviral drug, raises $2M | See David Hamilton’s story. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data techno... |
| 18.05.2007 | Prosetta, antiviral-drug developer, raises $2M | Prosetta, a San Francisco developer of new antiviral therapies, raised $2 million in early financing, VentureWire reports (subscription required). The company termed the funding a “series AAA” round that has the same terms as its earlier $1... |
| - | Takeda backs antiviral maker Prosetta Biosciences in $31M round | Prosetta Biosciences, a Bay Area startup developing small molecule antivirals, just closed out a $31 million Series D round. It’s developing drugs that could work against a whole library of viruses, including HIV, Ebola, Hepatitis C, influe... |